Gene Knowledge Graph
UTC
Standard

Medication use (calcium channel blockers)

NAT2 · rs73207888

Where this position leads

Condition: Medication Use as a Genetic Trait

Drug: Hydralazine

rs73207888 Condition: Medication Use as a Genetic Trait Medication Use as a Genetic Trait Condition Drug: Hydralazine Hydralazine Drug rs73207888 rs73207888 NAT2

What the study found

Who was studied 31,904 European ancestry cases, 172,474 European ancestry controls.

The effect Each copy of the T allele shifted the measure 0.123 higher (95% confidence interval 0.08-0.167); p = 3 × 10−8.

How common The T allele had a frequency of about 3% in the people studied.

Where it sits Chromosome 8, band 8p22 — between genes, 24.2 kb from NAT2.

What each result means

C/C Published research associates this genotype with typical/baseline likelihood of Medication use (calcium channel blockers) — no copies of the reported risk allele.
C/T Published research associates this genotype (one copy of the reported risk allele) with an intermediate association with Medication use (calcium channel blockers).
T/T Published research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Medication use (calcium channel blockers) compared to the general population.
Source
Genome-wide association study of medication-use and associated disease in the UK Biobank
Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, Yang J, Visscher PM, Wray NR
Nature communications · 2019 · PMID 31015401 · open access

Questions about rs73207888

What is rs73207888?

rs73207888 is a single position in the genome, in or near the NAT2 gene. Published research associates it with medication use (calcium channel blockers). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs73207888 linked to?

On MyGeneLog this position is linked to Medication Use as a Genetic Trait. The research behind each link, and its sources, are set out on that condition page.

Does rs73207888 affect how medicines work?

NAT2 carries pharmacogenomic findings for Hydralazine. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.

Does having rs73207888 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs73207888 come from?

GWAS Catalog, Nat Commun 2019, PMID:31015401. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Medication use (calcium channel blockers) (rs73207888). MyGeneLog™. https://www.mygenelog.com/variants/rs73207888

← See all variants